This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sterol 14 Alpha-Demethylase Inhibitor development. The report ...

Fate Therapeutics FATE reported a loss of 32 cents ... Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a ...

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sterol 14 Alpha-Demethylase Inhibitor development. The report provides ...

Cidara Therapeutics' CD388 is aimed at providing universal protection with a single yearly dose for each flu season. See why ...

ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline ...

ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline project: ...

Palvella Therapeutics (NASDAQ: PVLA) presented its Q1 2025 financial results and corporate update on May 15, 2025, highlighting progress in its rare disease pipeline and strong financial footing.

Summit Therapeutics PLC (NASDAQ: SMMT) presented its Q1 2025 earnings on May 1, highlighting the company’s continued focus on advancing its lead candidate Ivonescimab across multiple cancer ...

May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living ...

ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...